Data as of Jul 30
| +0.0388 / +5.34%|
The 3 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 2.50. The median estimate represents a +292.26% increase from the last price of 0.76.
The current consensus among 3 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.